Status:

WITHDRAWN

Ramelteon for Complex Insomnia in Veterans With PTSD

Lead Sponsor:

State University of New York at Buffalo

Collaborating Sponsors:

The VA Western New York Healthcare System

Conditions:

Insomnia

Eligibility:

All Genders

18-70 years

Phase:

PHASE4

Brief Summary

Obstructive sleep apnea is commonly reported in Veterans with post-traumatic stress disorder, which can potentiate symptoms of anxiety and depression, daytime symptoms and worsen nightmares. Continuou...

Detailed Description

Despite the overall improvement in PTSD symptomatology with CPAP therapy, adherence to CPAP is far worse in Veterans with PTSD (41%) compared to the general population with OSA (70%). Among the factor...

Eligibility Criteria

Inclusion

  • Age ≥18 years and ≤70 years old
  • Diagnosis of PTSD as determined by the intake conducted through the PTSD Clinic or the Mental Health Clinic
  • Documented obstructive sleep apnea by polysomnography (AHI≥5 or more/hour)
  • CPAP non adherence defined as less than 70% of nights with \>4h CPAP use despite addressing modifiable barriers for CPAP adherence
  • Psychotherapeutic treatment stable for at least 4 weeks prior to randomization
  • Capable of giving informed consent

Exclusion

  • Medical:
  • Acute or unstable chronic medical illness
  • History of narcolepsy and/or cataplexy Use of any of these medications: Fluvoxamine, fluconazole (Diflucan), itraconazole (Sporanox), and ketoconazole (Nizoral); cimetidine (Tagamet); clarithromycin (Biaxin); fluoroquinolones including ciprofloxacin, levofloxacin (Levaquin), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin), others; HIV protease inhibitors including indinavir (Crixivan), nelfinavir (Viracept), and ritonavir (Norvir, in Kaletra); nefazodone; rifampin
  • Treatment for seizure disorders
  • Pregnant or lactating
  • History of clinically significant hepatic impairment
  • History of hypersensitivity, intolerance, or contraindication to ramelteon
  • Unwilling to try or use CPAP
  • Psychiatric/Behavioral:
  • Diagnosis of current schizophrenia or schizoaffective disorder
  • Diagnosis of a substance dependence/abuse disorder in the past year
  • Severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to patient or others
  • Diagnosis of bipolar disorder
  • Consumption of more than two alcoholic beverages per night
  • Receiving behavioral or pharmacological treatment for insomnia

Key Trial Info

Start Date :

January 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2020

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03265951

Start Date

January 1 2018

End Date

June 30 2020

Last Update

April 9 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Veterans Affairs Medical Center in Buffalo

Buffalo, New York, United States, 14215